|
Market Closed -
Nasdaq Stockholm
12:00:00 2026-09-28 EDT
|
5-day change | 1st Jan Change | ||
| 1,650.50 SEK | +0.61% |
|
+0.30% | -3.11% |
| 08:43pm | AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination | RE |
| 08:17pm | AstraZeneca files US FDA application for Hutchmed lung cancer drug combination | RE |
| Market Cap | 257B 226B 214B 194B 364B 24,656B 366B 2,558B 988B 12,581B 964B 943B 40,429B | P/E 2026 * |
21.1x | P/E 2027 * | 18.4x |
|---|---|---|---|---|---|
| Enterprise Value | 277B 243B 230B 209B 392B 26,546B 394B 2,754B 1,064B 13,546B 1,038B 1,016B 43,529B | EV / Sales 2026 * |
4.38x | EV / Sales 2027 * | 4.01x |
| Free-Float |
96.62% | Yield 2026 * |
2.02% | Yield 2027 * | 2.14% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| AZN | Delayed | |
NYSE
| AZN | End-of-day quote | |
|
Nasdaq Stockholm
| AZN | Delayed | |
|
CBOE
| AZN | Real-time | |
|
CBOE
| AZNs | Real-time | |
|
CBOE
| AZN | Real-time | |
|
Tradegate
| ZEG | Real-time | |
|
Mexican S.E.
| AZN1 N | End-of-day quote | |
|
CBOE
| AZN | Real-time | |
|
Börse Stuttgart
| ZEG | Delayed | |
|
Deutsche Boerse AG
| ZEG | Delayed | |
|
Boerse Muenchen
| ZEG | Real-time | |
|
Berne S.E.
| 000982352 | End-of-day quote |
Last Transcript: AstraZeneca PLC
| 1 day | +0.61% | ||
| 1 week | +0.30% | ||
| Current month | +5.56% | ||
| 1 month | +5.87% | ||
| 3 months | -9.76% | ||
| 6 months | -8.20% | ||
| Current year | -3.11% |
| 1 week | 1,614 |  | 1,662 |
| 1 month | 1,507 | | 1,668.5 |
| Current year | 1,467 | | 1,925.5 |
| 1 year | 1,385 | | 1,925.5 |
| 3 years | 1,226 | | 1,925.5 |
| 5 years | 978.1 | | 1,925.5 |
| 10 years | 461.3 | | 1,925.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 66 | 2012-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 52 | 2021-07-31 |
Jeffrey Pott
CMP | Compliance Officer | - | 2022-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 1999-04-05 | |
Pascal Soriot
BRD | Director/Board Member | 66 | 2012-09-30 |
Philip Broadley
BRD | Director/Board Member | 65 | 2017-04-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.61% | +0.30% | - | - | 258B | |
| +0.11% | +1.71% | +63.52% | +117.61% | 1,055B | |
| +0.27% | +0.92% | +51.33% | +73.35% | 654B | |
| +0.73% | +0.68% | +20.70% | +74.90% | 467B | |
| -1.36% | -2.58% | +40.20% | +42.33% | 348B | |
| +1.34% | +4.53% | +23.37% | +29.55% | 275B | |
| -0.48% | -0.54% | +13.56% | +13.50% | 258B | |
| +0.85% | +6.35% | +53.17% | +54.39% | 224B | |
| +0.85% | +1.10% | +35.78% | +101.82% | 187B | |
| -0.30% | -2.98% | -27.62% | -61.28% | 171B | |
| Average | +0.18% | +0.52% | +30.45% | +49.57% | 404.26B | |
| Weighted average by Cap. | -0.01% | +1.00% | +40.69% | +69.85% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 63.17B 55.55B 52.53B 47.65B 89.49B 6,063B 90B 629B 243B 3,094B 237B 232B 9,942B | 67.01B 58.94B 55.73B 50.55B 94.93B 6,433B 95.48B 667B 258B 3,282B 252B 246B 10,548B |
| Net income | 12.04B 10.59B 10.02B 9.08B 17.06B 1,156B 17.16B 120B 46.32B 590B 45.22B 44.24B 1,896B | 13.77B 12.11B 11.45B 10.39B 19.51B 1,322B 19.63B 137B 52.97B 675B 51.71B 50.59B 2,168B |
| Net Debt | 19.69B 17.32B 16.38B 14.86B 27.9B 1,890B 28.06B 196B 75.74B 965B 73.94B 72.34B 3,100B | 11.93B 10.49B 9.92B 9B 16.9B 1,145B 17B 119B 45.88B 584B 44.79B 43.82B 1,878B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-28 | SEK 1,650.50 | +0.61% | 536,388 |
| 26-09-25 | SEK 1,640.50 | +0.64% | 392,299 |
| 26-09-24 | SEK 1,630.00 | -0.58% | 353,792 |
| 26-09-23 | SEK 1,639.50 | -1.65% | 368,047 |
| 26-09-22 | SEK 1,667.00 | +1.31% | 414,094 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
Select your edition
All financial news and data tailored to specific country editions
